Prognostic and Predictive Role of Vascular Endothelial Growth Factor Polymorphisms in Breast Cancer
- 6 January 2015
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 16 (1) , 79-94
Abstract
Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. The vascular endothelial growth factor (VEGF) pathway has been investigated extensively, due to its important role in angiogenesis. The major mediator of tumor angiogenesis is VEGF-A, frequently referred to as VEGF, which activates the VEGF receptor-2. The VEGF gene is located on chromosome 6 and constitutes a highly polymorphic gene. Numerous SNPs in the promoter, 5'- and 3'-untranslated regions (UTR) of VEGF gene have been recognized. This genetic variability possibly influences the production and function of VEGF. Subsequently, the VEGF SNPs may have an impact on breast cancer risk and disease outcome. Moreover, these SNPs may be of predictive value in patients receiving agents targeting the VEGF pathway. This review presents an update on the potential role of VEGF SNPs as prognostic and/or predictive markers in patients with breast cancer.Keywords
This publication has 77 references indexed in Scilit:
- VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional levelNucleic Acids Research, 2013
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancerBritish Journal of Cancer, 2013
- Evaluation of Functional Genetic Variants for Breast Cancer Risk: Results From the Shanghai Breast Cancer StudyAmerican Journal of Epidemiology, 2011
- Prospective analysis of the impact of VEGF‐A gene polymorphisms on the pharmacodynamics of bevacizumab‐based therapy in metastatic breast cancer patientsBritish Journal of Clinical Pharmacology, 2010
- The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumorsMolecular Cancer Therapeutics, 2009
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Association of survival and disease progression with chromosomal instability: A genomic exploration of colorectal cancerProceedings of the National Academy of Sciences, 2009
- VEGF-A splicing: the key to anti-angiogenic therapeutics?Nature Reviews Cancer, 2008
- Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExperimental Cell Research, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003